Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
Treatment of metastatic liver tumors using stereotactic ablative radiotherapy
Vimoj J Nair, Jason R Pantarotto, Division of Radiation Oncology, Ottawa Hospital Research Institute, University of Ottawa, Ottawa K1H 8L6, Ontario, Canada
Author contributions: Nair VJ and Pantarotto JR contributed equally to this work.
Supported by The Ottawa Hospital Foundation; the Ethel Ward Cushing Legacy Endowment Fund for a stereotactic ablative radiotherapy fellowship
Correspondence to: Jason R Pantarotto, MD, FRCPC, Chair, Division of Radiation Oncology, Ottawa Hospital Research Institute, University of Ottawa, 501 Smyth Road, Ottawa K1H 8L6, Ontario, Canada. jpantarotto@toh.on.ca
Telephone: +1-613-7377700 Fax: +1-613-2473511
Received: August 26, 2013
Revised: December 16, 2013
Accepted: January 6, 2014
Published online: February 28, 2014
Revised: December 16, 2013
Accepted: January 6, 2014
Published online: February 28, 2014
Core Tip
Core tip: The body of evidence related to the use of stereotactic ablative radiotherapy (SABR) in metastatic liver disease has substantially grown and evolved over the past decade. This review summarizes the current evidence supporting liver SABR with particular attention given to patient selection, target delineation, organ at risk dose volume constraints, response evaluation imaging and the various SABR techniques for delivering ablative radiotherapy to the liver.